The Chinese research team published a report in the British medical journal "The Lancet" on the 22nd, saying that they conducted a phase 1 clinical trial of a new coronavirus vaccine, and the results showed that the vaccine is safe and can induce a rapid immune response in the human body. 

The team led by Academician Chen Wei of the Institute of Biological Engineering, Institute of Military Medical Sciences, Academy of Military Sciences, and others led this clinical trial. The vaccine used in the trial was a recombinant adenovirus vector recombinant coronavirus vaccine. The team recruited 108 healthy adult volunteers in the trial, aged between 18 and 60 years old. These volunteers were divided into different groups and received different doses of vaccine.

The report said that within 28 days after vaccination, this vaccine showed good tolerance in different dose groups and did not cause serious adverse reactions.

Chen Wei said in a press release issued by The Lancet that Phase 1 clinical trials showed that inoculation with this recombinant adenoviral vector recombinant coronavirus vaccine can induce the production of virus-specific antibodies and T cells within 14 days. "These results represent a Important milestone".

However, Chen Wei also pointed out that the relevant results must be treated with caution. The development of a new coronavirus vaccine will face unprecedented challenges, and the ability to elicit an immune response does not necessarily mean that the vaccine can protect people from the new coronavirus infection. The development of the new coronavirus vaccine is very promising, but we still have a long way to go before this vaccine can be used by everyone."

The report said that the main limitations of this clinical trial include a small sample size, a short trial period, and a lack of a randomized control group. Therefore, further trials are needed to verify it.